[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100503462":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":49,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":72,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Zhongnan Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Integrin αvβ6-targeted PET in malignant tumors",null,"Participants: newly diagnosed malignant tumor confirmed by pathology or suspected lung cancer. Interventions: Participant who conforms to the inclusion criteria will undergo 18F-FDG and 68Ga-Trivehexin PET\u002FCT scans within 1 week.\n\nInterventions: Participant who conforms to the inclusion criteria will undergo 18F-FDG and 68Ga-Trivehexin PET\u002FCT scans within 1 week.\n\nObjectives: This study aims to assess and compare the diagnostic performance of 68Ga-Trivehexin and 18F-FDG PET\u002FCT for the detection of primary tumors, mediastinal lymph nodes and distant metastases, and to explore the correlation between 68Ga-Trivehexin accumulation and immunohistochemical β6 expression in NSCLC.",[13],"Diagnostic Test: PET\u002FCT scans",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","PET\u002FCT scans","Diagnostic Test: For 68Ga-Trivehexin PET\u002FCT, no special preparation was required. Approximately 50 min after an i.v. administration of \\[68Ga\\]Ga-Trivehexin with a dose of 1.85-2.22 MBq\u002Fkg, and the PET acquisition time was 2.5 min per bed.",[9],[21],{"name":22,"affiliation":5,"role":23},"Yong He, MD, PhD","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","+86-27-67812698","vincentheyong@163.com",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Zhongnan Hospital of Wuhan University","RECRUITING","Wuhan","Hubei","430071","China","CN",{"type":39,"coordinates":40},"Point",[41,42],114.26667,30.58333,{"lat":42,"lon":41},[45,48],{"name":46,"role":26,"phone":47,"phoneExt":10,"email":10},"Lei Zheng","+86-27-67812787",{"name":22,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":23,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Yong He","Chief of Department of Nuclear Medicine","100503462","integrin-v6-targeted-pet-in-malignant-tumors-100503462",false,"NCT05835570","Integrin αvβ6-targeted PET in Malignant Tumors","A Single-arm, Open-label, Single-center Clinical Study to the Evaluation of Integrin αvβ6-targeted Positron Emission Tomography (PET) for Malignant Tumors","Inclusion Criteria:\n\n* Participants with newly diagnosed malignant tumor confirmed by pathology or suspected lung cancer;\n* Age ≥18 years, regardless of gender;\n* No prior anti-tumor therapy (e.g., chemotherapy, radiotherapy, targeted therapy, or immunotherapy) before PET\u002FCT;\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1;\n* Female subjects of reproductive age, male subjects and their partners agree to use reliable contraceptive measures (e.g., abstinence, birth control pills, injectable contraceptives, or subcutaneous contraceptive implants) until 6 months after the completion of the study;\n* Participants should voluntarily consent to the clinical trial, and have the ability to understand and sign an informed consent form.\n\nExclusion Criteria:\n\n* Known allergy to injection or its excipients;\n* Severe liver or renal dysfunction;\n* Claustrophobia or other psychiatric disorders;\n* History of other malignant tumors;\n* Participation in another clinical trial within 30 days prior to PET\u002FCT scan;\n* Pregnant or breastfeeding women;\n* Refusal to participate or request for withdrawing from the clinical study;\n* Other conditions deemed unsuitable for inclusion by investigator.","ALL","18 Years","85 Years",{"count":63,"type":64},200,"ESTIMATED","OBSERVATIONAL","Malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. Integrin αvβ6 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous or reconstructed epithelial cells. A new PET probe, 68Ga-Trivehexin, targeting integrin αvβ6 has been developed with better affinity and selectivity than previous probes. Clinical data supports its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of tumors, providing a new and precise evaluation method for malignant tumors.",[68,69,70,71],"Malignant Neoplasm","PET\u002FCT","Non-Small Cell Lung Cancer","Breast Cancer, Metastatic",[73,74,75,76,77],"Non-small cell lung cancer","Breast cancer","Integrin-αvβ6","[68Ga]Ga-Trivehexin","Malignant tumors","2025-04-27",{"date":80,"type":81},"2025-04-30","ACTUAL",{"date":83,"type":81},"2023-01-01",{"date":85,"type":64},"2025-12-30",{"name":5,"class":6},1]